McDermott Will & Schulte, a global law firm

Grégoire Andrieux advises on mergers and acquisitions with a particular emphasis on leveraged buyouts and other complex private equity transactions.

He represents private equity institutions, family shareholders and entrepreneurs in domestic and cross-border acquisitions, refinancings, divestitures, build-ups and debt restructurings. 

Mark Fine focuses his practice on complex debt financing transactions for private equity houses, borrowers and lenders including direct lending, leveraged buyouts, domestic and cross-border syndicated lending, junior debt issuances, high yield offerings, special situations, distressed debt trading, portfolio acquisitions and restructurings. Mark has previously held the position of European General Counsel at Bain Capital Credit in London.

Mark has been described as “super responsive and involved as the partner” as well as “demonstrating strong commercial awareness during complex matters” by Chambers and Legal 500 note him to be “hugely intelligent and commercially savvy.”

Sharon Lamb focuses her practice on transactional and regulatory advice in the health and life sciences sector and leads McDermott’s UK Health and Life Sciences Practice Group.

Sharon advises on global transactional mandates, including mergers and acquisitions and joint ventures in health services, pharma and life sciences, digital health and health technologies. Sharon also provides strategic, regulatory and commercial support to UK and international clients on UK health and life sciences with a focus on health services, pharmaceuticals, medical devices, digital health and health data.

Sharon is widely recognized for her expertise on NHS and public law procurement, regulatory and contracting matters, including payment and reimbursement and market access. She has particular experience advising strategic and private equity investors in transactions and investments in health and life sciences.

Sharon is also well-versed in health care services governance and regulatory matters, NHS public private partnerships, procurements, joint ventures and shared working arrangements, mergers, acquisitions, health data and competition issues.

Sharon has practiced health and life sciences law in the UK since 2002 and is recognized in Chambers and Legal 500. Sharon has written and lectures widely on health and life sciences issues and has a wealth of experience with NHS law and policy, having worked on a 4-year part time secondment with the NHS and national health bodies in London.

Aymen Mahmoud is the European Head of Finance and Co-Head of both the London Transactions Group, and the London Finance, Restructuring and Special Situations Group. He is also Managing Partner of the Firm’s London office. He focuses his practice on complex debt financing transactions for private equity funds and their portfolio companies, hedge funds, corporate borrowers and issuers and other financial institutions including banks, direct lenders, family offices and other alternative sophisticated capital. His experience includes acting in respect of direct lending, leveraged buyouts, domestic and cross-border syndicated senior, second lien and mezzanine lending, distressed debt trading, portfolio acquisitions and restructurings, emerging markets and other debt securities, including high-yield debt offerings. Aymen also has significant experience in connection with pre-EBITDA and recurring revenue financings.

Aymen has been described as a “uniquely commercial and creative transaction leader” as well as “savvy, knowledgeable, always available and always on the ball” by Legal 500 and Chambers note him to be “extremely commercial and pragmatic.” He played a key role in first establishing the Loan Market Association forms of leveraged and high yield documentation and has been recognized in numerous significant awards, including Global Restructuring Review’s global “40 under 40” rankings in 2022, Mergerlinks‘ Top 30 Financing Lawyers in EMEA in 2023 and Financial News “Most Influential Lawyer” list in 2026.

Anthony Paronneau focuses his practice on a broad range of corporate and transactional matters, with a particular focus on the pharmaceutical, medical device, biotech, and healthcare sectors.

He has extensive experience representing life sciences companies, private equity funds, and venture capital firms in complex M&A and private equity transactions, including acquisitions, venture financings, joint ventures, and divestitures.

Anthony regularly advises emerging growth companies and VC investors on the structuring and negotiation of early- and late-stage funding rounds, and has acted on numerous high-profile cross-border and domestic transactions involving leading innovators in the healthtech and biotech spaces.

In addition, he counsels life sciences clients on strategic partnerships, collaborations, licensing agreements, and distribution arrangements, supporting their growth and commercialization strategies across all stages of development.

Emmanuelle Trombe is the co-head of the Firm’s Life Sciences industry practice. She represents pharmaceutical, medical device and bio-pharmaceutical companies globally in transactional matters in relation to M&A and divestitures, joint ventures and strategic partnerships, large-scale projects, outsourcing projects, product development, licensing agreements and regulatory matters. She also advises venture capital funds and bio-pharmaceutical companies in connection with a broad range of financing activities. As well as co-heading the Firm’s Life Sciences Group, Emmanuelle serves as an elected member of the Firm’s Management Committee.

Emmanuelle is distinguished in Chambers Europe and Legal 500 EMEA in life sciences transactions, where she is highly recommended for her experience in the pharmaceutical, healthcare, biotech and medical devices industries and described as very responsive, smart, flexible and business-minded. She has been distinguished as the Lawyer of the Year in Life Sciences for 2024.

Eleanor (Ellie) West centres her practice on private equity transactions and mergers and acquisitions.  Ellie works across a wide range of sectors, and has particular expertise in the health care and life sciences industries.

Ellie regularly advises domestic and international private equity sponsors on transactional matters (including leveraged buy-outs, growth capital investments, add-on acquisitions and the implementation of management incentive plans).  She also advises a range of multi-national corporations on cross-border acquisitions, disposals and restructuring transactions.